Vialwirebiotech, curated
November 21, 2026, 5:50 PM
July 20, 2026
- 2:38 PM · BioPharma Dive2:38 PMTempus to acquire cancer test maker Personalis for $1.5B — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMImmix investors skittish over exec's sexual assault arrest — BioWorld
- 12:00 PM · BioWorld12:00 PMRinascera launches with two rare genetic skin disease therapies — BioWorld
- 11:57 AM · BioPharma Dive11:57 AMPain drugmaker Latigo outlines plans to go public — BioPharma Dive
- 11:38 AM · Pharmaceutical Technology11:38 AMWhat Ojemda’s JCA reveals about new era of clinical HTA in Europe — Pharmaceutical Technology
- 10:18 AM · Pharmaceutical Executive10:18 AM<![CDATA[FDA Clears Consano’s IND for C-1101 ]]> — Pharmaceutical Executive
- 9:00 AM · BioWorld9:00 AMGan & Lee Pharmaceuticals synthesizes new CK1α molecular glue degraders — BioWorld
- 9:00 AM · BioWorld9:00 AMFunding to expand Sightera Biosciences’ AI-discovered programs — BioWorld
- 9:00 AM · BioWorld9:00 AMVeraxa Biotech receives feedback on BiTAC-TCE program — BioWorld
- 8:41 AM · Drug Discovery World8:41 AMPhase II triple-negative breast cancer trial restarts — Drug Discovery World
- 7:00 AM · SCMP — Tech7:00 AM‘Systemic leap’: China’s drug innovation push yields bumper crop — SCMP — Tech
- 6:59 AM · STAT News
- 6:46 AM · Pharmaceutical Technology6:46 AMNovartis and Takeda drugs gain rare blood cancer routine use on NHS — Pharmaceutical Technology
- 6:07 AM · Pharmaceutical Technology6:07 AMSamsung Biologics to acquire PolyPeptide in $1.81bn cash deal — Pharmaceutical Technology
- 4:45 AM · Drug Discovery World4:45 AMEpilepsyGTx partners with ClearPoint for gene therapy delivery — Drug Discovery World
- 12:00 AM · FT — Pharmaceuticals12:00 AMAstraZeneca highlights rare diseases in $80bn revenue push — FT — Pharmaceuticals